# US 2015/0087829 A1 · Process and intermediates for preparing gpr40 agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0087829 A1
- Document ID: US20150087829A1
- Status: Published application
- Kind: A1
- Application number: 14/494,631
- Filed: 2014-09-24
- Published: 2015-03-26
- Earliest claimed: 2013-09-26
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Georg DAHMANN; Holger WAGNER; Matthias ECKHARDT; Markus FRANK; Marco SANTAGOSTINO; Juergen SCHNAUBELT; Uwe STERTZ; Thorsten PACHUR
- Web page: https://patentgrep.com/patent/US20150087829A1

## CPC

- C07D 307/80: Radicals substituted by oxygen atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula I wherein RS denotes F or CF3, Ra denotes H or C1-4-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.

## Claims

### Claim 1

A compound of formula (I)
wherein:
RS is F or CF3;
Ra is H or C1-4-alkyl;
Z is a leaving group or an optionally substituted or protected hydroxyl group,
or a salt of the compound of formula (I) wherein Ra is H.

### Claim 2 (depends on 1)

The compound of formula (I) according to claim 1, wherein Ra is —CH3.

### Claim 3 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
Z is Cl, Br, I, or an optionally substituted or protected hydroxyl group.

### Claim 4

(6-(R)-(4-Bromo-7-fluoroindan-1-yloxy)benzofuran-3-yl)acetic acid, or a salt thereof.

### Claim 5

(6-(R)-(4-Bromo-7-fluoroindan-1-yloxy)benzofuran-3-yl)acetic acid methyl ester or a salt thereof.

### Claim 6 (depends on 1)

A process for preparing a compound of formula (I′) according to claim 1, comprising reacting a compound of formula (II) with a compound of formula (III):
wherein RS is F or CF3, Ra is C1-4-alkyl and, Z′ is a leaving group or a protected hydroxyl group.

### Claim 7 (depends on 6)

The process of claim 6, further comprising ester cleavage to convert Ra to H.

### Claim 8 (depends on 6)

The process of claim 6, wherein Ra is —CH3.

### Claim 9 (depends on 6)

The process of claim 6, wherein Z is Cl, Br, I, or a substituted hydroxyl group.

### Claim 10

A process for preparing indanyloxydihydrobenzofuranylacetic acids of formulae IV.I, IV.II, and IV.III
wherein in formula IV.I
R1 is selected from the group consisting of a phenyl ring, a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, —O—, and —S—, wherein optionally a second ring is annulated to the phenyl or heteroaromatic ring, and the second ring is 5- or 6-membered, partially unsaturated or aromatic and optionally contains 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, —O—, and —S— with the proviso that only up to two of the heteroatoms are O and S and no O—O, S—S, and S—O bond is formed, and wherein in the second ring independently of the presence of heteroatoms 1 or 2 CH2 groups are optionally replaced by —C(═O)—, —S(═O)—, or —S(═O)2—, and the phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring are substituted with one group R3, and each of the phenyl ring, tetrazolyl ring, heteroaromatic ring, annulated phenyl ring, and annulated heteroaromatic ring is optionally additionally substituted with 1 to 4 groups independently selected from R4, and wherein in the heteroaromatic ring and/or the second ring the H-atom in one or more NH groups is replaced by RN or R3;
R3 is C1-6-alkyl, C2-6-alkenyl, C3-6-cycloalkyl, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, C1-6-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, or C1-4-alkyl-S(═O)2, wherein each alkyl and cycloalkyl group and each alkyl and cycloalkyl sub-group within the groups mentioned is substituted with 1 to 3 groups independently selected from R5 and optionally substituted with 1 or more F atoms, or
C1-4-alkyl-C(═O)—, heterocyclyl-C(═O)—, HNRN—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, phenyl-NRN—C(═O)—, heteroaryl-NRN—C(═O)—, HO2C—, C1-4-alkyl-O—C(═O)—, C3-6-cycloalkyl-O—C(═O)—, heterocyclyl-O—C(═O)—, —NHRN, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-C(═O)NRN—, phenyl-C(═O)NRN—, heteroaryl-C(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, C3-6-cycloalkyl-S(═O)2NRN—, heterocyclyl-S(═O)2NRN—, phenyl-S(═O)2NRN—, heteroaryl-S(═O)2NRN—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, C3-6-cycloalkyl-S—, heterocyclyl-S—, phenyl-S—, heteroaryl-S—, C3-6-cycloalkyl-S(═O)—, heterocyclyl-S(═O)—, phenyl-S(═O)—, heteroaryl-S(═O)—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, phenyl-S(═O)2—, heteroaryl-S(═O)2—, HNRN—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, phenyl, and heteroaryl, wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 to 3 groups independently selected from R5 and optionally substituted with 1 or more F atoms, and wherein each phenyl and heteroaryl group is optionally substituted with 1 to 5 substituents independently selected from R6;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NH— or —O—, a saturated or partially unsaturated O5-7-cycloalkyl group wherein 1 CH2 group is replaced by —C(═O)—, —NH—, —O—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —NH— or —O—, a second CH2 group is replaced by —NH—, —C(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
a saturated or partially unsaturated O5-7-cycloalkyl group wherein 2 CH2 groups are replaced by —NH— or 1 CH2 group by —NH— and the other by —O— and a third CH2 group is replaced by —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
wherein heteroaryl is selected from
a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC═N— unit this group is optionally replaced by —NH—C(═O)—;
wherein in heteroaryl and heterocyclyl rings with one or more NH groups each of them is replaced by NRN or NR5,
R4 is selected from the group consisting of F, Cl, Br, I, CN, —OH, C1-4-alkyl, C3-6-cycloalkyl, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, —NRNH, C1-4-alkyl-NRN—, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, and C1-4-alkyl-S(═O)2—, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms;
R5 is selected from the group consisting of Cl, Br, I, C1-4-alkyl-, CN, C3-6-cycloalkyl, heterocyclyl-C(═O)—, H2N—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, phenyl-NRN—C(═O)—, heteroaryl-NRN—C(═O)—, HO—C(═O)—, C1-4-alkyl-O—C(═O)—, —NHRN, C1-4-alkyl-NRN—, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-C(═O)NRN—, phenyl-C(═O)NRN—, heteroaryl-C(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, C3-6-cycloalkyl-S(═O)2NRN—, heterocyclyl-S(═O)2NRN—, phenyl-S(═O)2NRN—, heteroaryl-S(═O)2NRN—, —OH, C1-4-alkyl-O—, C1-4-alkyl-O—C1-4-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl-O—, phenyl-O—, heteroaryl-O—, C1-4-alkyl-S—, C3-6-cycloalkyl-S—, heterocyclyl-S—, phenyl-S—, heteroaryl-S—, C1-4-alkyl-S(═O)—, C3-6-cycloalkyl-S(═O)—, heterocyclyl-S(═O)—, phenyl-S(═O)—, heteroaryl-S(═O)—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, phenyl-S(═O)2—, heteroaryl-S(═O)2—, H2N—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, phenyl, and heteroaryl, wherein any alkyl, cycloalkyl and heterocyclyl group or sub-group within the groups mentioned is optionally substituted with 1 or more F atoms and optionally substituted with 1 or 2 groups independently selected from H3C—, HO—, H3C—O—, and —CN;
wherein heterocyclyl is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NRN— or —O—,
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —C(═O)—, —NRN—, —O—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 1 CH2 group is replaced by —NRN— or —O—, a second CH2 group is replaced by —NRN—, —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
a saturated or partially unsaturated C5-7-cycloalkyl group wherein 2 CH2 groups are replaced by —NRN— or 1 CH2 group by —NRN— and the other by —O—, and a third CH2 group is replaced by —O(═O)—, —S(═O)— or —S(═O)2— and/or 1 CH group by N;
and wherein heteroaryl is selected from
a tetrazolyl ring, and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently selected from ═N—, —NH—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC═N— unit this group is optionally replaced by —NRN—C(═O)—, and wherein in heteroaromatic rings with one ore more NH groups each of them is replaced by NRN, and each heteroaryl group is optionally substituted with 1 to 3 substituents independently selected from F, Cl, —CH3, —CN, and —O—CH3;
R6 is selected from the group consisting of F, Cl, Br, I, CN, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl-, C1-4-alkyl-O—C1-4-alkyl-, RNHN—, C1-4-alkyl-O—, —S(═O)—C1-4-alkyl, and S(═O)2—C1-4-alkyl, wherein any alkyl and cycloalkyl group or sub-group within the groups mentioned is optionally substituted with one or more F atoms; and
RN is independently selected from the group consisting of H, C1-4-alkyl, C1-4-alkyl-C(═O)—, C1-4-alkyl-NH—C(═O)—, C1-4-alkyl-N(C1-4-alkyl)-O(═O)—, C1-4-alkyl-O—C(═O)—, and C1-4-alkyl-S(═O)2—;
wherein in formula IV.II
(Het)Ar is linked via a carbon atom and is selected from the group (Het)Ar-G1 consisting of phenyl, naphthyl and a mono- or bicyclic heteroaromatic group having 5 to 10 ring member atoms of which 2 to 9 ring members are carbon atoms and either
one ring member is an unsubstituted or substituted heteroatom selected from N, NH, NRN-II, O, S, S(═O), and S(═O)2, or
one ring member is N and a second ring member is selected from N, NH, NRN-II, O, S, S(═O), and S(═O)2, or
two ring members are N and a third ring member is selected from N, NH, NRN-II, O, S, S(═O), and S(═O)2,
wherein in naphthyl the ring not attached to the indanyl-O atom of formula IV.II is optionally partially saturated,
wherein in bicyclic heteroaromatic groups the ring not attached to the indanyl-O atom of formula IV.II is optionally partially saturated, while at least one aromatic ring includes a heteroatom, and optionally
one ring member in the partially or fully saturated bridge is replaced by N, NH, NRN-II, O, S, S(═O), or S(═O)2, or
one ring member in the partially or fully saturated bridge is replaced by N, NH, or NRN-II and second ring member is replaced by NH, NRN-II, O, S, C(═O), S(═O), or S(═O)2, or
two not vicinal ring members in a fully saturated bridge are replaced by O atoms,
wherein any of these groups is optionally and independently substituted with 1 to 5 R1-II groups;
R1-II is selected from the group consisting of F, Cl, Br, I, CN, NO2, NH2, C1-4-alkyl-NH—, (C1-4-alkyl)2N—, C1-4-alkyl, C2-4-alkenyl, C2-4-alkinyl, OH, HO—C1-4-alkyl, C1-4-alkyl-O—, C1-4-alkyl-O—C1-4-alkyl, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl, and C3-6-cycloalkyl-O—, wherein any alkyl and cycloalkyl group or submoiety is optionally substituted with 1 to 5 F atoms;
RN-II is selected from the group consisting of C1-4-alkyl, C3-4-alkenyl, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, C1-4-alkyl-C(═O)—, C1-4-alkyl-S(═O)2—, and C3-6-cycloalkyl-, wherein any alkyl and cycloalkyl group or submoiety is optionally substituted with 1 to 5 F atoms;
wherein in formula IV.III
R1-III is selected from the group consisting of a monocyclic or bicyclic group having 5 to 12 ring member atoms of which 4 to 11 ring members are C atoms and 1 to 3 ring members are heteroatoms selected from N and NRN-III, or
1 or 2 ring members are heteroatoms selected from N and NRN-III and 1 ring member is selected from O and S, or
1 ring member is N and 2 ring members are independently selected from O and S, with the proviso that no O—O, S—S, or S—O bond is formed,
wherein the ring member atom attached to the —CH2— group in formula IV.III is an N atom,
wherein 1 CH2 ring member attached to a ring member N atom is optionally replaced by a —O(═O)— group,
wherein the monocyclic or bicyclic group is saturated or partially unsaturated, with the proviso that in bicyclic groups the ring attached to the —CH2— group in formula IV.III is not aromatic, and
wherein the bicyclic group is optionally a fused, bridged, or spiro ring system;
wherein any of these groups is optionally and independently substituted with 1 to 3 R2-III groups;
R2-III is selected from the group consisting of F, Cl, Br, I, C1-4-alkyl, NC—, HO—C1-4-alkyl, HO—, C1-4-alkyl-O—, C1-4-alkyl-O—C1-4-alkyl, C1-4-alkyl-S—, C1-4-alkyl-S(═O)—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl-, and C3-6-cycloalkyl-O—, wherein any alkyl and cycloalkyl group or submoiety is optionally substituted with 1 to 3 F atoms; and
RN-III is selected from the group consisting of H, C1-4-alkyl-, C1-4-alkyl-C(O)—, and C1-4-alkyl-O—C(O)—;
wherein any alkyl group or sub-group is straight-chained or branched, unless specified otherwise,
the process comprising:
a) performing asymmetric catalytic hydrogenation in the presence of a transition metal catalyst and a chiral auxiliary, optionally in the presence of a base, on the compound of formula I or a salt thereof:
wherein RS is F or CF3, Ra is H or C1-4-alkyl, and Z is a leaving group or protected hydroxyl group, and
b) reacting the compound of formula V based on the identity of Z, as follows:
b-1) if Z is Cl, Br, I, or a substituted hydroxyl group, reacting the compound of formula V with a compound of formula R1—X, wherein X is B(OH)2, B(OCMe2CMe2O), B(O2CCH2)2NCH3, BF3K, ZnHal, or MgHal (where Hal is Cl, Br, or I), to obtain a compound of formula IV′, which is subsequently saponified if Ra of the compound of formula IV′ is C1-4-alkyl, to obtain a compound of formula IV
b-2) if Z is B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], reacting the compound of formula V with a compound of formula R1—X1, wherein X1 is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, or trifluoromethylsulfonyloxy, to obtain a compound of formula IV′, which is subsequently saponified if Ra of the compound of formula IV′ is C1-4-alkyl, to form a compound of formula IV
b-3) if Z is OH, reacting the compound of formula V with a compound of formula (Het)Ar—X2, wherein X2 is F, Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, trifluoromethylsulfonyloxy, B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], to obtain a compound of formula IV′″, which is subsequently saponified if Ra of the compound of formula IV′″ is C1-4-alkyl, to form a compound of formula IV″
b-4) if Z is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, trifluoromethylsulfonyloxy, B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], reacting the compound of formula V with a compound of formula (Het)Ar—OH, to obtain a compound of formula IV′, which is subsequently saponified if Ra of the compound of formula IV′ is C1-4-alkyl, to form a compound of formula IV
or
b-5) if Z is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, trifluoromethylsulfonyloxy, reacting the compound of formula V with a compound of formula R1-III—CH2—X3, wherein X3 is B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], and subsequent saponification of a compound of formula IVV, wherein Ra is C1-4-alkyl, to obtain a compound of formula IVV, which is subsequently saponified if Ra of the compound of formula IVV is C1-4-alkyl, to form a compound of formula IVIV

### Claim 11 (depends on 10)

The process of claim 10, wherein the transition metal catalyst is Ir, Rh, Ru, Pd, or Fe catalyst.

### Claim 12 (depends on 10)

The process of claim 10, wherein Z is Cl, Br, I, or an optionally substituted or protected hydroxyl group.

### Claim 13 (depends on 10)

A process for preparing indanyloxydihydrobenzofuranylacetic acids of formulae IV.I, IV.II, and IV.III
wherein R1, (Het)Ar, and R1-III are defined as in claim 10, comprising:
c) reacting the compound of formula I, wherein RS is F or CF3 and Ra is H or C1-4alkyl, based on the identity of Z, as follows:
c-1) if Z is Cl, Br, I, or a substituted hydroxyl group, reacting the compound of formula I with a compound of formula R1—X, wherein X is B(OH)2, B(OCMe2CMe2O), B(O2CCH2)2NCH3, BF3K, ZnHal, or MgHal (where Hal is Cl, Br, or I), to obtain a compound of formula VI,
c-2) if Z is B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], reacting the compound of formula I with a compound of formula R1—X1, wherein X1 is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, or trifluoromethylsulfonyloxy, to obtain a compound of formula VI
c-3) if Z is OH, reacting the compound of formula I with a compound of formula (Het)Ar—X2, wherein X2 is F, Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, trifluoromethylsulfonyloxy, B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], to obtain a compound of formula VI′
c-4) if Z is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, trifluoromethylsulfonyloxy, B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], reacting the compound of formula I with a compound of formula (Het)Ar—OH, to form a compound of formula VI′
or
c-5) if Z is Cl, Br, I, methylsulfonyloxy, phenylsulfonyloxy, p-tolylsulfonyloxy, or trifluoromethylsulfonyloxy, reacting the compound of formula I with a compound of formula R1-III—CH2—X3, wherein X3 is B(OH)2, B(OC1-4-alkyl)2, B[OC(CH3)2C(CH3)2O], B(O2CCH2)2NCH3, or BF3M [where M is Li+, Na+, K+, NH4+, +N(CH3)4, or other cationic metal or ammonium group], to obtain a compound of formula VI″
and
d) performing asymmetric catalytic hydrogenation in the presence of a transition metal catalyst and a chiral auxiliary, optionally in the presence of a base, on the compound of formula VI″ or a salt thereof, wherein Z″ is R1, O-(Het)Ar, or CH2—R1-III

### Claim 14 (depends on 13)

The process of claim 13, wherein the transition metal catalyst is Ir, Rh, Ru, Pd, or Fe catalyst.

### Claim 15 (depends on 13)

The process of claim 13, wherein Z is Cl, Br, I, or an optionally substituted or protected hydroxyl group.

### Claim 16

A process for preparing indanyloxydihydrobenzofuranylacetic acids of formula V
wherein RS is F or CF3, Ra is H or C1-4-alkyl, and Z is a leaving group or an optionally substituted or protected hydroxyl group, and salts thereof, the process comprising performing an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary, optionally in the presence of a base, applied to a (in case Ra is H), on a compound of formula I or a salt thereof:
